SCHEMBL6366983

SCHEMBL6366983

Cc1cccc([C@H](CO)C(=O)O)c1Cl

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.47
KMT2A Q03164 3/20 0.47
CTSA P10619 1/20 0.36
PPARG P37231 1/20 0.35
PPARA Q07869 1/20 0.35
ITGB1 P05556 2/20 0.34
ITGA4 P13612 2/20 0.34
CXCL8 P10145 1/20 0.34
POLB P06746 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
HPGD P15428 2/20 0.33
ERCC5 P28715 1/20 0.33
FEN1 P39748 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ALDH1A1 P00352 1/20 0.33
HSD17B10 Q99714 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP3A4 P08684 1/20 0.33
CYP2C9 P11712 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6366984 1.00 MEN1 (0.47) MEN1KMT2ACTSAPPARGPPARA
SCHEMBL6366981 1.00 MEN1 (0.47) MEN1KMT2ACTSAPPARGPPARA
SCHEMBL1857873 0.82 ACP3 (0.43) MEN1KMT2ACTSAPPARGPPARA
SCHEMBL24977455 0.80 MEN1 (0.47) MEN1KMT2APPARGPPARAKDM4E
SCHEMBL8854194 0.77 LMNA (0.41) MEN1KMT2ACTSACXCL8POLB
SCHEMBL22969909 0.77 CXCL8 (0.50) MEN1KMT2ACXCL8HPGDKDM4E
SCHEMBL23886595 0.75 MEN1 (0.51) MEN1KMT2ACXCL8ALDH1A1CYP1A2
SCHEMBL7812432 0.75 MEN1 (0.51) MEN1KMT2ACXCL8ALDH1A1CYP1A2
SCHEMBL23886599 0.75 MEN1 (0.51) MEN1KMT2ACXCL8ALDH1A1CYP1A2
SCHEMBL30370919 0.75 MEN1 (0.51) MEN1KMT2ACXCL8ALDH1A1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6838478-B2 Amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB (SE) 2005-01-04 US disclosed
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors ASTRAZENECA AB 2002-02-14 US disclosed
US-6255301-B1 CARDIOVASCULAR DISORDERS; ANTICOAGULANT; PROTEASE INHIBITORS ASTRAZENECA AB (SE) 2001-07-03 US disclosed
EP-0910573-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS Astra Aktiebolag (SE) 1999-04-28 EP disclosed
WO-1997046577-A1 NEW AMINO ACID DERIVATIVES AND THEIR USE AS THROMBIN INHIBITORS ASTRA AKTIEBOLAG (SE) 1997-12-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020019371-A1 New amino acid derivatives and their use as thrombin inhibitors F2, SERPINC1, FGB MEN1 2803/4885KMT2A 3943/4885CTSA 521/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.